2024
Personalized risk assessment of new onset depression in long-term cancer survivors.
Taylor M, Westvold S, Long J, Hyslop T, Wang S, Cecchini M, Leapman M, Leeds I, Lustberg M, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Personalized risk assessment of new onset depression in long-term cancer survivors. Journal Of Clinical Oncology 2024, 42: e13798-e13798. DOI: 10.1200/jco.2024.42.16_suppl.e13798.Peer-Reviewed Original ResearchHistory of depressionIncidence of depressionCumulative incidence of depressionRisk of developing depressionLong-term survivorsPredictors of depressionCancer survivorsDisease specific factorsCumulative incidenceNon-HispanicHigher risk of developing depressionRectal cancerLong-term cancer survivorsBreast cancer survivorsCensus tract povertyColon cancerEpisodes of bipolar I disorderPrevalence of depressionMean survival time modelsDiagnosis of depressionReceipt of treatmentAssociated with prior historyHormone receptor statusPatients aged <Adjuvant endocrine therapyPD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchMP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. MP57-08 COST EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY (PSMA-PET) FOR THE EVALUATION OF BIOCHEMICAL RECURRENT PROSTATE CANCER IN THE UNITED STATES HEALTHCARE SYSTEM. Journal Of Urology 2024, 211: e940. DOI: 10.1097/01.ju.0001009420.83948.eb.08.Peer-Reviewed Original ResearchPD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. PD45-11 TEMPORAL AND REGIONAL PATTERNS OF PROSTATE CANCER POSITRON EMISSION TOMOGRAPHY IMAGING AMONG COMMERCIAL INSURANCE BENEFICIARIES IN THE UNITED STATES. Journal Of Urology 2024, 211: e972. DOI: 10.1097/01.ju.0001008792.09108.b4.11.Peer-Reviewed Original ResearchImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rateTemporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Karnes R, Kunst N, Wang S, Ma X, Gross C. Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States. Journal Of Clinical Oncology 2024, 42: 34-34. DOI: 10.1200/jco.2024.42.4_suppl.34.Peer-Reviewed Original ResearchProportion of patientsProstate cancerPSMA-PETPET imagingProstate specific membrane antigen positron emission tomographyDiagnosis of prostate cancerProstate cancer visualizationPSMA PET imagingPSMA-targeted agentsPositron emission tomography imagingCochran-Armitage testDynamic cohort studyPositron emission tomographyCommercial insurance beneficiariesEmission tomography imagingChi-square testCancer visualizationCholine tracersCohort studyProstateTreatment decisionsBlue Cross Blue Shield AxisCochran-ArmitageEmission tomographyInsurance beneficiariesRacial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
2023
Beneficial Effect of Societal Factors on APOE-ε2 and ε4 Carriers’ Brain Health: A Systematic Review
Aravena J, Lee J, Schwartz A, Nyhan K, Wang S, Levy B. Beneficial Effect of Societal Factors on APOE-ε2 and ε4 Carriers’ Brain Health: A Systematic Review. The Journals Of Gerontology Series A 2023, 79: glad237. PMID: 37792627, PMCID: PMC10803122, DOI: 10.1093/gerona/glad237.Peer-Reviewed Original ResearchBrain healthSocietal factorsAPOE ε4Cognitive outcomesApolipoprotein E ε4APOE ε4 carriersAPOE ε2Beneficial effectsΕ4 carriersSystematic reviewAPOE ε4 allele carriersHigh schoolAPOE ε2 carriersDetrimental effectsBasic needsHealthy People 2030Beneficial impactExternal stimuliHarmful impactSDH categoriesInclusion criteriaAllele carriersAlzheimer's diseaseCommunity-level policySocial determinantsRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseDemographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer.
Westvold S, KC M, Fan J, Hyslop T, Spees L, Wang S, Silber A, Oeffinger K, Dinan M. Demographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer. Journal Of Clinical Oncology 2023, 41: e24105-e24105. DOI: 10.1200/jco.2023.41.16_suppl.e24105.Peer-Reviewed Original ResearchLong-term breast cancer survivorsBreast cancer survivorsLong-term survivorsCardiovascular diseaseCancer survivorsHigh riskCancer stageRace/ethnicityClinical characteristicsDiagnosis yearBreast cancerEvidence of CVDNon-Hispanic black patientsNon-metastatic breast cancerLong-term cancer survivorsCox proportional hazards modelCurative-intent surgeryCVD hazard ratiosNon-oncologic outcomesCancer-specific survivalStage III diseaseInitial cancer diagnosisDiagnosis of CVDRace/ethnicity groupsChi-square test
2022
Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma. Blood 2022, 140: 5270-5271. DOI: 10.1182/blood-2022-164741.Peer-Reviewed Original Research
2021
Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Yang SC, Wang JD, Wang SY. Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data. Scientific Reports 2021, 11: 12180. PMID: 34108586, PMCID: PMC8190256, DOI: 10.1038/s41598-021-91852-6.Peer-Reviewed Original ResearchConceptsLead-time biasNational Lung Screening TrialStage shiftStage IALife expectancyCancer patientsLung cancerCalendar yearNationwide cancer registryBenefits of screeningLung cancer patientsReal-world studyLung cancer diagnosisMean life expectancyTomography screeningCancer RegistryLE gainsCancer screeningEarly diagnosisScreening TrialGeneral populationSame pathologyYounger agePathologyCancer diagnosisCost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. Journal Of Clinical Oncology 2021, 39: 2386-2396. PMID: 34019456, PMCID: PMC10166354, DOI: 10.1200/jco.21.00831.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsTreatment strategiesRadiation treatmentDuctal carcinomaAge 40Risk reductionAdjuvant treatment strategiesGood-risk patientsLarge randomized trialsAdverse event ratesOptimal treatment strategyRelative risk reductionCohort of womenBreast cancer casesLow-value careQuality of lifeCost-effectiveness analysisBase-case resultsHormonal therapyAdjuvant treatmentMost patientsPatient ageSecondary malignanciesRandomized trialsRecurrence rateAssociations Between Health Literacy and End-of-Life Care Intensity Among Medicare Beneficiaries
Luo Q, Shi K, Hung P, Wang SY. Associations Between Health Literacy and End-of-Life Care Intensity Among Medicare Beneficiaries. American Journal Of Hospice And Palliative Medicine® 2021, 38: 626-633. PMID: 33472379, DOI: 10.1177/1049909120988506.Peer-Reviewed Original ResearchConceptsAggressive EOL careLow health literacyEOL careHealth literacyMedicare beneficiariesHospital deathCare intensityHigher oddsEOL care intensityLife care intensityPatient-provider communicationProportion of decedentsMonths of lifeDays of lifeHospice enrollmentHL scoreMultivariable analysisHospice useCare measuresRetrospective analysisLife careMedicare feeService decedentsDecedentsCareTrend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016
Yang SC, Gross C, Wang JD, Wang SY. Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016. Journal Of General Internal Medicine 2021, 36: 3589-3591. PMID: 33469753, PMCID: PMC8606484, DOI: 10.1007/s11606-020-06586-4.Peer-Reviewed Original ResearchEnd-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis
Davidoff AJ, Canavan ME, Prsic E, Saphire M, Wang SY, Presley CJ. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis. Supportive Care In Cancer 2021, 29: 3921-3932. PMID: 33389087, DOI: 10.1007/s00520-020-05964-2.Peer-Reviewed Original ResearchConceptsCancer-directed therapySymptom management servicesLung cancerMedicare beneficiariesCare contentYounger ageEarlier hospice enrollmentLife care patternsLung cancer decedentsPercentage of patientsClaims-based analysisMethodsThis retrospective studyMost Medicare beneficiariesNonhospice settingsCancer decedentsUsual careHospice enrollmentSymptom managementRetrospective studyMedicare databaseSkilled nursingHigh comorbidityCare intensityMedicare claimsMultinomial logistic regression
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsTreatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan
Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLOS ONE 2020, 15: e0240542. PMID: 33052942, PMCID: PMC7556438, DOI: 10.1371/journal.pone.0240542.Peer-Reviewed Original ResearchRacial and Ethnic Disparities in Population-Level Covid-19 Mortality
Gross CP, Essien UR, Pasha S, Gross JR, Wang SY, Nunez-Smith M. Racial and Ethnic Disparities in Population-Level Covid-19 Mortality. Journal Of General Internal Medicine 2020, 35: 3097-3099. PMID: 32754782, PMCID: PMC7402388, DOI: 10.1007/s11606-020-06081-w.Peer-Reviewed Original Research